

The dilemma of Tocilizumab therapy for a patient with critical COVID-19 disease and neutropenia: Case report and review of the literature

Ahmad Al Bishawi¹, Shiema Abdalla¹, Marwa Askar¹, Wael Kanjo¹, Amal Sameer¹, Gihan Mustafa¹, Hamad Abdel Hadi¹, Muna AlMaslamani², and Alaaeldin Abdelmajid³

¹Hamad Medical Corporation

²Hamad Medical Corp

³Hamad General Hospital

April 26, 2022

Abstract

Our patient is a 39-year-old male with normal baseline blood parameters who presented with COVID-19 infection, associated with neutropenia and then progressed to critical disease culminating into CSS. Based on risks and benefits evaluation, he was treated with Tocilizumab reinforced with G-CSF leading to full recovery including reversal of neutropenia.

Hosted file

Tocilizumab Submitted.docx available at <https://authorea.com/users/438539/articles/566911-the-dilemma-of-tocilizumab-therapy-for-a-patient-with-critical-covid-19-disease-and-neutropenia-case-report-and-review-of-the-literature>